Drug Profile
Metformin effervescent - EffRx
Alternative Names: Effervescent metformin oral solution - EffRx; EX-404Latest Information Update: 02 Jun 2023
Price :
$50
*
At a glance
- Originator EffRx
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Polycystic ovary syndrome
Most Recent Events
- 29 May 2023 EffRx has been acquired by Abiogen Pharma
- 28 Feb 2023 No recent reports of development identified for phase-I development in Polycystic-ovary-syndrome(In adolescents) in USA (PO, Liquid)
- 28 Jan 2020 Phase II/III development is ongoing for Polycystic ovary syndrome (In adults) in USA (PO) (EffRx pipeline, January 2020)